Skip to main content

Table 2 The baseline characteristics of the participants by intervention, placebo groups and overall

From: Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan

Baseline characteristic

Intervention (GKT137831) group (n = xxx)

Placebo group (n = xxx)

Percentage standardised difference

Overall (n = xxx)

Values

Missing, n (%)

Values

Missing, n (%)

Values

Missing, n (%)

Urine albumin–creatinine ratio (UACR) (log-transformed)

       

 Mean (standard deviation (SD))

       

Estimated glomerular filtration rate (eGFR) (log-transformed)

       

 Mean (SD)

       

Gender

       

 Male, n (%)

       

 Female, n (%)

       

Age (years),

       

 Mean (SD)

       

Ethnicity

       

 xx, n (%)

       

 Other, n (%)

       

Clinical variables

       

 Systolic blood pressure (mmHg), mean (SD)

       

 Diastolic blood pressure (mmHg), mean (SD)

       

 Use of angiotensin-converting-enzyme inhibitor (ACEi), n (%)

       

 Use of angiotensin II receptor blocker (ARB), n (%)

       

 Body mass index (kg/m2), mean (SD)

       

 Duration of diabetes mellitus at baseline (years), mean (SD)

       

 Glycated haemoglobin (HbA1c %), median (25th–75th percentile)

       
Back to article page

Trials

ISSN: 1745-6215